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Abstract
Introduction: Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein that has been implicated in arthritis
pathogenesis in a mouse model. The aim of this study is to detect FSTL1 expression and to further assess its
potential utility as a biomarker of joint damage in osteoarthritis (OA) patients.
Methods: FSTL1 expression was detected by real-time PCR, western blot and immunohistochemistry (IHC) in the
synovial tissues (STs) and by IHC in the articular cartilage from OA patients and control trauma patients. The serum
and synovial fluid (SF) FSTL1 concentrations were measured by ELISA in OA patients and control individuals. Linear
regression analyses were used to assess correlations between the serum FSTL1 levels and the clinical characteristics
in OA patients.
Results: The FSTL1 mRNA and protein levels were substantially elevated in the STs from OA patients compared
with those from control trauma patients. The FSTL1 expression was strong in the cytoplasm of the synovial and
capillary endothelial cells of the STs, but weak in the chondrocytes of the articular cartilage from OA patients.
Furthermore, the serum and SF FSTL1 concentrations were significantly higher in OA patients than in respective
control subjects. Interestingly, the serum and SF FSTL1 levels were markedly higher in female OA patients than in
males. Importantly, bivariate regression analysis revealed that the serum FSTL1 levels in female OA patients had
significant correlations with Kellgren and Lawrence (KL) grade, joint space narrowing (JSN) and the Western Ontario
McMaster and Universities Osteoarthritis (WOMAC) stiffness subscale, an inverse correlation with height, and
marginal correlations with the total WOMAC score and the WOMAC function subscale. Multivariate regression
analysis revealed that the serum FSTL1 levels correlated independently with KL grade in female OA patients.
Bivariate analysis also revealed that the serum FSTL1 levels correlated significantly with age and disease duration,
and they correlated marginally with high sensitivity C-reactive protein (hs-CRP) and KL grade in male OA patients.
Conclusions: Increased FSTL1 expression may be a characteristic of OA patients. FSTL1 is a potential serum
biomarker that may reflect the severity of joint damage, and further studies are required to evaluate its potential
application for monitoring the course of the disease and the efficacy of therapies in OA patients.
Keywords: FSTL1, osteoarthritis, biochemical marker, KL grade, WOMAC score
* Correspondence: yujiwang@sohu.com; ldw20319750826@hotmail.com
† Contributed equally
1Department of Orthopaedics, Changzhou No.2 People’s Hospital, the
Affiliated Hospital of Nanjing Medical University, 29 Xinglong Alley,
Changzhou, 213003, P. R. China
2State Key Laboratory of Genetic Engineering, Institute of Genetics, School of
Life Sciences, Fudan University, 220 Handan Road, Shanghai, P. R China
Full list of author information is available at the end of the article
Wang et al. Arthritis Research & Therapy 2011, 13:R193
http://arthritis-research.com/content/13/6/R193
© 2011 Wang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Osteoarthritis (OA) is characterized by the destruction
of articular cartilage and subchondral bone and by syno-
vitis [1,2]. The progressive deterioration of joint struc-
ture and function has prompted studies to identify
potential biomarkers of the damage to articular cartilage
and subchondral bone as well as markers to monitor the
progression of the disease and facilitate the design of
proper treatment [3,4]. In addition, many of the biomar-
kers have also been implicated in OA pathogenesis,
broadening our insight into this process.
FSTL1 is an extracellular glycoprotein originally cloned
from a mouse osteoblast cell line as a transforming growth
factor b (TGFb)-inducible gene [5]. FSTL1 is widely
expressed in human tissues and induced by ischemic stress
and proinflammatory mediators [6-9]. Although the func-
tions of FSTL1 at the molecular level remain largely
unknown, several reports indicate that FSTL1 is involved
in arthritis pathogenesis. Tanaka et al. [10] first identified
FSTL1 as an autoantigen in systemic rheumatic diseases,
and found FSTL1 and its autoantibody in synovial fluid
(SF) and plasma in patients with rheumatoid arthritis
(RA). Further studies demonstrate that FSTL1 has poten-
tial preventive effects on joint destruction by inhibiting the
production of matrix metalloproteinases (MMPs) and
cytokines both in synovial cells in vitro and in mouse
models in vivo [11,12]. Consistently, one recent report
reveals that FSTL1 plays an immunomodulatory role in
heart allograft transplantation by inhibition of the proin-
flammatory cytokines, IL6, IL17A and IFNg [13]. Another
report indicates that FSTL1 protects the kidneys from
acute nephrotoxic injury by inhibiting IL-1b production
[14]. However, conflicting data have also shown that
FSTL1 is a new proinflammation mediator that causes and
aggravates arthritis by promoting the expression of IL-1b,
TNFa and IL-6 and by enhancing the IFNg signaling path-
ways in a mouse model [8,15].
Although the effects of FSTL1 on inflammation and
immunity are complex and controversial, serum FSTL1
concentrations have been assessed in healthy individuals
and patients with acute coronary syndrome (ACS), and
shown to relate to ACS mortality during follow-up [16].
A recent study also reveals that serum FSTL1 levels are
increased in systemic on-set juvenile rheumatoid arthri-
tis (JRA) and suggests that FSTL1 may represent a bio-
marker of disease activity in systemic JRA [17]. Our
previous report indicates that the serum FSTL1 levels
are elevated in patients with RA, ulcerative colitis, sys-
temic lupus erythematosus, Sjögren’s syndrome, sys-
temic sclerosis and polymyositis/dermatomyositis [9].
Furthermore, the serum FSTL1 levels correlate with
inflammatory status and represent a new biomarker for
disease activity in the RA population [9].
However, FSTL1 expression and its correlations with
the clinical characteristics in OA patients have not been
assessed until now. The present study is aimed at deter-
mining FSTL1 levels and further evaluating its clinical
potential practicality as a serum biomarker reflecting the
severity of joint damage in OA patients.
Materials and methods
Subjects
All OA and RA patients included in this study were
diagnosed according to the American College of Rheu-
matology (ACR) clinical classification criteria [18-20].
The samples of synovial tissues (STs) from 33 OA
patients and 10 RA patients were obtained by total knee
joint replacement or arthroscopic synovectomy. These
tissue samples were inspected visually to ensure that
inflamed tissues with obvious edema and erythema were
included. The control knee tissue samples were taken
from seven trauma patients, including four patients with
femur fractures and two patients with tibial and fibular
fractures who underwent transarticular intramedullary
interlocking nail insertion and one patient who under-
went amputation due to severe trauma. These trauma
patients had healthy joints with intact synovium. Most
of the tissue samples were stored at -70°C immediately
upon acquisition until use for mRNA and protein
extraction. Some tissue samples were also fixed in 4%
paraformaldehyde and embedded in paraffin. The SF
samples were collected from 42 OA patients, 16 RA
patients and 6 trauma patients who served as controls.
The SF samples were collected by means of needle
aspiration with the use of a sterile technique during
knee joint surgery. The SF samples were placed in a
sterile polypropylene tube and then frozen at -70°C until
analysis. The mRNA sample from one trauma control
was not acquired because of the relatively small tissue
b l o c k s .W ew e r ea l s ou n a b l et oa c q u i r et h eS Fs a m p l e
from another trauma patient. The clinical and demo-
graphic characteristics of these patients and of the con-
trols whose SF samples were available are shown in
Table 1.
The serum samples were collected by venipuncture
from 168 OA patients including 158 knee and 10 hip
OA patients. The clinical data were carefully reviewed
to exclude any other forms of inflammatory joint dis-
eases, systemic autoimmune diseases, as well as tumors
or heart, liver or kidney diseases. The OA patients
included untreated individuals (88%), patients treated
with nonsteroidal anti-inflammatory drugs (NSAIDs)
(10%) or patients treated with joint space injection of
sodium hyaluronate (2%). A total of 63 apparently
healthy control individuals (HCs) who were without reg-
ular medication or chronic drug use or other chronic
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samples were acquired and stored immediately at -20°C
until measurement. The demographic, clinical and
laboratory characteristics of the subjects for whom the
serum samples were available are summarized in Table
2. In this study, 32 OA patients (8 male and 24 female)
had the paired serum and SF samples; 13 OA patients
had the paired serum and ST samples; 17 OA patients
had the paired ST and SF samples. A total of 10 OA
patients had the matched serum, SF and ST samples.
The erythrocyte sedimentation rate (ESR) was mea-
sured by the Westergren method. The serum high sensi-
tivity C-reactive protein (hs-CRP) and rheumatoid factor
(RF) levels were determined in a clinical laboratory
using a latex photometric immunoassay. A 100-mm
visual analogue scale (VAS) was used to calculate
patients’ baseline pain score. The Western Ontario
McMaster and Universities Osteoarthritis (WOMAC)
Index Likert Format 3.1 was used to assess the patients’
physical function [21].
The OA severity was determined using weight-bearing
anteroposterior radiographs of the affected joints, which
were evaluated according to the Kellgren and Lawrence
(KL) classification [22]. The grade of OA was described
as follows: Grade 0, no radiographic findings of osteoar-
thritis; Grade 1, minute osteophytes of doubtful clinical
significance; Grade 2, definite osteophytes with unim-
paired joint space; Grade 3, definite osteophytes with
moderate joint space narrowing (JSN); Grade 4, definite
osteophytes with severe JSN and subchondral sclerosis.
Each radiograph was examined independently by two
investigators (YW and TD) in a blinded manner. The
inter-rater reliability and intra-rater reliability for the
investigators were high (the weighted kappa for inter-
rater reliability was 0.93; the kappa for intra-rater relia-
bility was 0.94). Nine inconsistent radiographs were
arbitrated by another investigator (NX). Only the
patients for whom serum samples were available had
complete KL and partial WOMAC scores. Because we
mostly used banked samples of ST and SF, we did not
obtain KL and WOMAC scores from these patients,
except in the cases of those who had paired serum
samples.
Collection of the ST, SF and serum samples was per-
formed according to the medical ethics regulations of
Nanjing Medical University. This study was approved by
Nanjing Medical University Review Board, and written
permissions were requested and received from all
patients and HCs.
Real-time PCR
Total RNA extraction, retrotranscription and real-time
PCR were carried out as previously described with
minor modifications [9]. Briefly, total RNA was
extracted from the minced cryogenic tissues using miR-
Neasy Mini kit (Qiagen, Basel, Switzerland) according to
the manufacturer’s instructions. In-column digestion of
contaminating DNA was performed using the RNase-
Free DNase Set (Qiagen). Total RNA (1 μg) was
reverse-transcribed using the ReverTra Ace kit (Toyobo,
Osaka, Japan) according to the manufacturer’si n s t r u c -
tions. Real-time PCR was performed using SYBR Green
(Toyobo) in a Roche LightCycler
® 480 (Roche Applied
Science, Indianapolis, IN, US). The primer sequences for
Table 1 Characteristics and SF FSTL1 levels in the subjects investigated
a
Con OA RA Male OA Female OA
Number 6 42 16 11 31
Age (years)
b 32 (30-49) 67 (60-72) 61 (54-70) 70 (55-75) 67 (60-72)
Sex (M/F) 4/2 11/31 2/14 - -
Disease duration (years)
b - 1.0 (0.5-3.0) 2.0 (0.5-4.5) 0.9 (0.2-2.8) 1.0 (0.5-6.0)
FSTL1 levels (μg/L)
b 6.80 15.66 39.80 11.65 16.54
(6.02-7.32) (12.04-19.80) (22.74-273.80) (8.57-13.50) (14.09-27.53)
aIncluded all subjects for whom SF samples were available and part of subjects for whom tissue samples were available.
bExpressed as the median (25
th to 75th
percentile). Con, control trauma patients; FSTL1, follistatin-like protein 1; OA, osteoarthritis; RA, rheumatoid arthritis.
Table 2 Characteristics and serum FSTL1 levels in the subjects investigated
a.
HC OA Male HC Male OA Female HC Female OA
Number 63 168 29 48 34 120
Age (years)
b 37 (29-47) 62 (54-69) 35 (31-43) 61 (54-72) 39 (29-52) 62 (54-69)
Disease duration (years)
b - 1.0 (0.3-3.9) - 0.5 (0.2-3.0) - 1.0 (0.5-5.0)
FSTL1 levels (μg/L)
b 2.93 19.03 2.50 5.64 3.32 24.40
(2.35-3.69) (7.41-27.98) (2.17-2.96) (3.81-8.75) (2.43-8.67) (15.65-31.17)
aIncluded all subjects for whom serum samples were available.
bExpressed as the median (25
th to 75th percentile). FSTL1: follistatin-like protein 1; HC: healthy
control individual; OA: osteoarthritis.
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were as follows: FSTL1, 5’ -CGATGGACACTGCAAA-
GAGA-3’ (forward) and 5’-CCAGCCATCTGGAAT-
GATCT-3’ (reverse); GAPDH, 5’-AGGGCTGCTT
TTAACTCTGGT-3’ (forward) and 5’-CCCCACTT-
GATTTTGGAGGGA-3’ (reverse). The comparative
threshold cycle (Ct) method was used for relative quan-
tification of mRNA.
Western blot
The minced cryogenic tissues were lysed and boiled in
Laemmli buffer (50 mmol/L Tris-HCl pH 6.8, 2% SDS,
0.1% bromophenol blue, 10% glycerol, 5% b-mercap-
toethanol) SDS-PAGE was performed on 12% polyacry-
lamide, and the proteins transferred to nitrocellulose
membranes. A goat anti-human FSTL1 polyclonal anti-
body (R&D Systems, Minneapolis, Minnesota, US) and
actin AC-40 (Sigma-Aldrich, St. Louis, MO, US) were
used to detect FSTL1 and b-actin expression,
respectively.
Immunohistochemistry
The samples of STs from four control trauma patients
and four OA patients, as well as cartilage tissues from
one control trauma patient and one OA patient, were
assessed by immunohistochemistry (IHC). IHC staining
was performed on archival formalin fixed, paraffin-
embedded tissues, using the peroxidase technique as
described previously [9]. Briefly, sections were deparaffi-
nized and rehydrated. Epitope retrieval was performed
in citrate buffer (pH 6) in a water bath at 95°C for 15
minutes with cooling for 10 minutes before immunos-
taining. The tissues were incubated with the anti-FSTL1
antibody (1:400 dilution) overnight at 4°C after blocking
and then exposed to a biotinylated secondary linking
antibody (Boster, Wuhan, China) for 20 minutes. Biotin
detection was performed with peroxidase-conjugated
streptavidin (Boster). Finally, the slides were incubated
with a 3, 3’-diaminobenzidine (DAB) solution (Boster)
for 1 to 5 minutes and counterstained with hematoxylin
for 1 minute. The sections were washed between incu-
bations with Tris-buffered saline (pH 7.6). A goat poly-
clonal immunoglobulin G (IgG) was used as a negative
control throughout the procedure. Each section was
examined independently by two investigators (DL and
YW) in a blinded manner.
Enzyme-linked immunosorbent assay (ELISA)
The serum and SF FSTL1 concentrations were detected
using a standard quantitative sandwich ELISA (Ground-
work Biotechnology Diagnosticate, San Diego, CA, US)
with a detection limit of 100 pg/ml. The SF samples
were pretreated with 5 mg/ml hyaluronidase (Sigma-
Aldrich, St. Louis, MO, US) dissolved in phosphate
buffered saline for 5 minutes and clarified by means of
centrifugation at 5,000 g for 10 minutes. Aliquots of 50
μl of the collected SF supernatant or serum samples
were added to microwells. A total of 100 μlo ft h ec o n -
jugated antibody was added to each microwell and
mixed thoroughly with the samples. After extensive
washing, a substrate solution was added that reacts with
enzymes to produce a color change. The optical densi-
ties were determined using a microplate reader
Elx808™ (Bio-Tek Instruments, Winooski, VT, USA).at
450 nm. Software Gene 5 (BioTek Instruments) was
used to analyze all materials and produce a standard
curve. The concentrations were reported as μg/L. All
analyses and calibrations were performed in duplicate.
Statistical analysis
Statistical analyses were performed using Prism and
Instat (GraphPad Software, San Diego, CA, US) and
SPSS 13.0 software (SPSS Inc., Chicago, IL, US). The
significance of the differences was evaluated using the
Kruskal-Wallis test among multiple groups and using
the Mann-Whitney U test between groups. The paired
serum and SF samples were evaluated by the Wilcoxon
matched pairs test. Bivariate linear regression analysis
was used to evaluate the relationships between serum
FSTL1 levels and other parameters. Multivariate linear
regression analysis was performed to identify variables
that were independently associated with serum FSTL1
levels. Variables that were not normally distributed were
transformed to their natural logarithm (ln) for the
regression analyses. The Kolmogorov-Smirnov test was
used to assess the normal distribution of variables. For
regression analysis, the binary variables were coded as
follows: hypertension (0 = no hypertension, 1 = hyper-
tension), diabetes (0 = no diabetes, 1 = diabetes), bilat-
eral joints involved (0 = single joint involved, 1 =
bilateral joints involved) and JSN (0 = no JSN, 1 = JSN).
All quoted P values were 2-tailed, and P values less than
0.05 were considered significant.
Results
Increased FSTL1 expression in the STs from OA patients
To assess the FSTL1 expression levels in OA patients,
we first compared FSTL1 mRNA levels in the STs of
OA, RA and control trauma patients. Consistent with
our previous report [9], the FSTL1 mRNA levels were
upregulated in the STs of RA patients by approximately
1.71-fold compared with the controls. Interestingly, we
also found that the FSTL1 mRNA levels in OA patients
were elevated by approximately 1.49-fold and 2.55-fold
compared with RA patients and the controls, respec-
tively (Figure 1A). However, the FSTL1 mRNA levels
showed no difference between male and female OA
patients. Furthermore, we detected FSTL1 protein
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samples. The FSTL1 protein levels were markedly higher
in the STs from OA and RA patients than in the con-
trols (Figure 1B). These results indicate that upregula-
tion of FSTL1 expression generally occurs in the STs of
OA and RA patients.
Localization of FSTL1 in the STs from OA patients
To further assess the FSTL1 expression levels and tissue
distribution, we stained the sections of the STs from both
OA patients and control trauma patients using a specific
antibody for FSTL1 (Figure 2A-2H). The FSTL1 staining
was at a relatively low level in the normal STs from the
controls (Figure 2A-2B), but was much more intense in
the STs from OA patients compared with the controls
(Figure 2A-2H). The FSTL1 staining was clearly seen in
the cytoplasm of the synoviocytes in the lining and sub-
lining from the STs of OA patients (Figure 2C-2H).
Interestingly, the FSTL1 expression was also stronger in
the endothelial cells (ECs) of the OA samples than in the
controls (Figure 2B, D, E and 2H), suggesting a possible
role in angiogenesis in arthritis. In contrast, the FSTL1
staining was invisible in most of the infiltrated lympho-
cytes. Finally, we assessed FSTL1 expression on the sec-
tions of the articular cartilage from OA patients and the
controls (Figure 2I-2L). The FSTL1 staining was weak or
even absent in the chondrocytes of the articular cartilage,
and showed no differences between OA patients and the
controls (Figure 2I-2L). Interestingly, the FSTL1
expression was markedly stronger in the synovial cells
and ECs than in the chondrocytes from the same OA
patient (Figure 2G-2H and Figure 2K-2L).
Elevated serum and SF FSTL1 levels in OA patients
Next, we examined the serum FSTL1 levels in HCs and
OA patients. The serum FSTL1 levels were much higher
in OA patients than in HCs (Figure 3A and Table 2).
Furthermore, we stratified all individuals by sex and
compared the serum FSTL1 levels. We found that the
serum FSTL1 levels were significantly elevated in female
individuals compared to male individuals among both
the HCs and the OA patients (Figure 3A and Table 2).
Then, we selected age-matched HCs and compared the
serum FSTL1 levels between the HCs and OA patients
in male and female groups. The serum FSTL1 levels
were also significantly higher in OA patients than in the
HCs in both groups (data not shown). The serum
FSTL1 distribution was heterogeneous between male
and female OA patients (Additional file 1, Figure 1S).
We also compared the SF FSTL1 levels among OA, RA
and control trauma patients. The SF samples were pre-
treated with hyaluronidase to reduce their viscosity. The
SF FSTL1 levels were increased significantly after treat-
ment or following several cycles of freezing and thawing
(data not shown), suggesting that FSTL1 could be teth-
ered in a large molecule complex or released from vis-
cous contaminants. The FSTL1 levels in the SF samples
of the OA patients were significantly higher than those
Figure 1 Increased FSTL1 expression in the STs from OA patients. (A) FSTL1 mRNA expression in the cryogenic tissue samples from control
trauma patients (Con), OA and RA patients, male OA patients and female OA patients. The results are expressed in relative units. The horizontal
lines represent the medians. Each point represents an individual value. *, P < 0.05; **, P < 0.01. (B) FSTL1 protein expression in the cryogenic
tissue samples from control trauma patients (Con1 to Con7: normal STs from 7 different trauma controls), RA patients (RA1 to RA5: RA STs from
5 different RA patients) and OA patients (OA1 to OA28: OA STs from 28 different OA patients). The male individuals are represented in italics.
The FSTL1 immunoreactive band appears as a band with an electrophoretic mobility corresponding to 46 kDa. b-actin was used as a loading
control. FSTL1, follistatin-like protein 1; Con, control trauma patients; RA, rheumatoid arthritis; OA, osteoarthritis; ST, synovial tissue.
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(Figure 3B and Table 1). The SF FSTL1 levels were also
significantly higher in the female OA patients compared
to the males (Figure 3B and Table 1). Moreover, we
compared the serum FSTL1 levels with the SF FSTL1
levels in 32 paired samples from the same OA patients
and did not observe significant differences in both the
male and female OA groups (data not shown).
Serum FSTL1 levels correlate with KL grade in OA
patients
Finally, we assessed the relationship between the serum
FSTL1 levels and the demographic, clinical and
laboratory characteristics in OA patients. We separately
evaluated the relationship in male and female OA
patients because serum FSTL1 distribution was
obviously heterogeneous between the sexes (Additional
file 1, Figure 1S).
The serum FSTL1 levels were distributed normally in
120 female OA patients. Bivariate regression analysis
revealed that the serum FSTL1 levels had significant
correlations with KL grade and JSN, but an inverse cor-
relation with height. Moreover, the serum FSTL1 levels
correlated significantly with the WOMAC stiffness sub-
scale, and they correlated marginally with the total
WOMAC score and WOMAC function subscale.
Figure 2 Immunohistochemical staining of FSTL1 in the STs and articular cartilage from control trauma patients and OA patients. (A-
B) The STs from control trauma patients. The synovial cells of the lining and sublining with little or weak FSTL1 immunostaining are shown. (C-
H) The STs from OA patients. The synovial cells of the lining and sublining with positive FSTL1 immunostaining are shown. (I-L) The articular
cartilage from control trauma patients (I-J) and OA patients (K-L). The chondrocytes with little or weak FSTL1 immunostaining are shown. The STs
(C and D; E and F; G and H) were collected from three different OA patients. The STs (G and H) and articular cartilage (K and L) were collected
from the same OA patients. All tissue samples were counterstained with hematoxylin. (A, C, E, G, I and K) Original magnification, ×100. (B, D, F, H,
J and L) Original magnification, ×400. The negative controls stained with polyclonal goat IgG (original magnification, ×100) are shown in the
insets (A, C, E, G, I and K). Arrows indicate the capillary endothelial cells in the STs from control trauma patients (B) and OA patients (D, F and H).
Representative images from one of three separate experiments with similar results are shown. FSTL1, follistatin-like protein 1; IgG,
immunoglobulin G; OA, osteoarthritis; ST, synovial tissue.
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the other variables included (Table 3). Next, we focused
on 112 female patients with OA of the knee by exclud-
ing 8 female patients with OA of hip and obtained simi-
lar results (Additional file 1, Table 1S). In a multivariate
regression analysis that used serum FSTL1 concentra-
tions as the dependent variable and included age, body
weight, height, disease duration, bilateral joints involved,
hypertension, diabetes, hs-CRP, RF and KL grade as the
independent variables, only KL grade was independently
associated with the serum FSTL1 levels (Table 4). The
total r
2 value of this model was 0.24.
The serum FSTL1 levels correlated significantly with
age, disease duration and RF, and they correlated mar-
g i n a l l yw i t hh s - C R Pa n dK Lg r a d ei n4 8m a l eO A
patients by bivariate analysis (Table 5). The serum
FSTL1 levels were not correlated with the other vari-
ables included. Furthermore, we focused on 46 male
patients with OA of the knee by excluding 2 male
patients with OA of the hip and obtained similar results
(Additional file 1, Table 2S). No variable was indepen-
dently associated with the serum FSTL1 levels in the
multivariate models among the male patients.
Discussion
In this study, we found that the FSTL1 expression levels
were increased in the ST, SF and serum samples from
OA patients. The serum FSTL1 levels correlated with
KL grade and JSN in the female OA patients, and they
also correlated marginally with KL grade in the males.
These findings suggest that FSTL1 may represent a new
potential serum biochemical marker reflecting the sever-
ity of joint damage in OA patients.
The FSTL1 mRNA expression levels were elevated in
the STs of OA patients compared with RA patients and
control trauma patients. However, the serum and SF
FSTL1 levels were highest in RA patients among three
groups, including those described in our previous study
[9]. These discrepancies may be due to the fact that the
STs of RA patients have a higher density of proliferative
synovial cells, which could secrete much more FSTL1
into the serum and SF under the conditions of the
proinflammatory microenvironment, although they have
a relatively lower mean cellular FSTL1 mRNA
expression.
The serum and SF FSTL1 levels were markedly
increased in OA patients. Long-term chronic inflamma-
tion may stimulate synovial cell hyperplasia and neovas-
cularization in the OA patients [23,24]. The large areas
of synovitis with proliferative synovial cells and the
increased vascular bed could induce more FSTL1 pro-
d u c t i o ni nt h eO Ap a t i e n t s .W ea l s of o u n dt h a tt h e
female OA patients had higher serum and SF FSTL1
levels than the male OA patients. It is possible that
female OA patients suffered from more severe synovitis
and joint damage, and therefore produced more secreted
Figure 3 Elevated serum and SF FSTL1 levels in OA patients. (A) Serum FSTL1 concentrations in HCs, OA patients, male HCs, male OA
patients, female HCs and female OA patients. (B) SF FSTL1 concentrations in control trauma patients (Con), OA and RA patients, male OA
patients and female OA patients. The horizontal lines represent the median values. Each point represents an individual value. Con, control
trauma patients; FSTL1, follistatin-like protein 1; HC, healthy control individual; OA, osteoarthritis; RA, rheumatoid arthritis; SF, synovial fluid. **, P <
0.01; ***, P < 0.001.
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observe obvious sex difference in the levels of the tissue
FSTL1 mRNA expression between the sexes. It is possi-
ble that the relatively small tissue sample size overrode
the FSTL1 tissue difference between the sexes.
Thus far, biomarkers from cartilage, bone and syno-
vium have been identified in OA patients. The available
data have shown that biomarkers from STs perform well
in assessing quantitative and dynamic variations in joint
remodeling [3]. In this study, we found that FSTL1
expression was strong in the synovial cells and ECs in
the STs but relatively low or even absent in the chon-
drocytes of the articular cartilage in OA patients. These
findings suggested that FSTL1 could be a biomarker
from synovium. Furthermore, FSTL1 may represent a
biomarker of the burden of disease (severity of joint
damage) according to the recently proposed BIPED (i.e.
burden of disease, investigative, prognostic, efficacy of
intervention and diagnostic) classification of OA bio-
markers [25]. Our findings also revealed a greater sensi-
tivity of serum FSTL1 levels as an OA biomarker in the
female OA patients than in the males. However, we can-
not exclude the effects of a relatively small sample size
for the male OA patients. Larger cohort studies will be
required to better define the potential role of serum
FSTL1 as a structural burden biomarker of OA in male
patients.
Table 4 Independent association of serum FSTL1 levels
with baseline characteristics in 120 female OA patients
a.
Characteristics B P value
Age, years -0.215 0.051
Body weight, kg -0.148 0.207
Height, cm -0.165 0.471
Disease duration, years 0.023 0.972
Bilateral joints involved -2.633 0.254
Hypertension -2.386 0.263
Diabetes 2.294 0.447
Hs-CRP, mg/l 1.151 0.142
RF, IU/ml 0.192 0.801
KL grade 4.458 <0.0001
aMultivariate linear regression analysis was used to assess variables associated
with serum FSTL1 concentrations. B, unstandardized B coefficient; Hs-CRP,
high sensitivity C-reactive protein; IU, international units; KL, Kellgren and
Lawrence; OA, osteoarthritis; RF, rheumatoid factor.
Table 3 Baseline characteristics of female OA patients according to serum FSTL1 levels.
Female serum FSTL1 levels (μg/L)
First quartile Second quartile Third quartile Fourth quartile P r
(1.94-15.65) (15.65-24.35) (24.45-31.08) (31.20-54.20)
Number 30 30 30 30
Age (years) 62 (52-67) 66 (58-72) 62 (56-70) 61 (54-65) 0.592 0.049
Disease duration (years) 1 (0.5-3.0) 1 (0.2-6.3) 1.5 (0.5-3.6) 2 (0.5-8.5) 0.282 0.099
Height, cm 160 (155-164) 158 (156-162) 158 (158-162) 158 (155-162) 0.049 -0.181
Weight, kg 65 (60-70) 62 (55-70) 65 (60-70) 60 (55-65) 0.272 -0.101
BMI 25.3 (22.9-27.1) 25.1 (22.0-28.1) 25.8 (24.3-27.5) 23.9 (22.6-26.1) 0.667 -0.040
Single/dual knee (hip) 22/8 21/9 21/9 22/8 0.795 0.024
Hypertension 10 (33%) 9 (30%) 12 (40%) 6 (20%) 0.309 -0.094
Diabetes 5 (17%) 2 (7%) 6 (20%) 2 (7%) 0.894 -0.012
Hs-CRP (mg/L) 1.4 (0.6-4.1) 2.2 (1.1-4.7) 1.9 (1.0-4.6) 1.9 (0.9-11.3) 0.113 0.146
ESR
a 13 (6-26) 11 (8-20) 10 (7-20) 11 (5-20) 0.270 -0.114
RF 6.9 (2.7-12.9) 8.6 (2.8-14.6) 7.3 (3.1-12.7) 7.7 (3.5-14.6) 0.910 0.010
Pain (VAS mm)
b 60 (50-70) 60 (50-78) 55 (40-78) 50 (36-70) 0.166 -0.143
WOMAC score (all normalized/100)
c
Pain subscale 57 (50-61) 57 (48-70) 50 (46-64) 61 (53-71) 0.129 0.177
Stiffness subscale 47 (42-56) 50 (38-61) 58 (42-71) 64 (52-73) 0.015 0.279
Function subscale 56 (52-68) 59 (50-68) 63 (48-77) 73 (58-90) 0.079 0.204
Total Score 56 (48-63) 56 (48-66) 61 (46-73) 68 (56-78) 0.051 0.214
KL grade (0-4) 6/7/13/1/3 0/5/8/7/10 0/4/10/10/6 0/6/2/11/11 <0.0001 0.406
JSN 4 (13%) 17 (57%) 16 (53%) 22 (73%) <0.0001 0.419
Data are number (%) or median (25
th to 75th percentile). Linear regression was used to evaluate the relationships between FSTL1 levels and baseline
characteristics and to calculate P values and the correlation coefficient, r. (Disease duration, hs-CRP, ESR and RF in the female OA patients were not normally
distributed and were entered as ln-transformed variables).
aData from ESR were available for 95 patients;
bData from Pain VAS were available for 95 patients;
cData from the total WOMAC score were available for 84 patients, and the pain subscale, stiffness subscale and function subscale were available for 75 patients,
respectively. BMI, body mass index; ESR, erythrocyte sedimentation rate; FSTL1, follistatin-like protein 1; Hs-CRP, high sensitivity C-reactive protein; JSN, joint
space narrowing; KL, Kellgren and Lawrence; OA, osteoarthritis; RF, rheumatoid factor; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster
Universities.
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Page 8 of 11The serum FSTL1 levels correlated with the
WOMAC stiffness subscale and they also correlated
marginally with the total WOMAC score and
WOMAC function subscale in female OA patients.
These findings suggested that the increased serum
FSTL1 levels were associated with relief of symptoms,
including stiffness and function loss, in these patients.
Previous reports indicate that FSTL1 ameliorates
arthritis by inhibiting the production of proinflamma-
tory mediators [11,12]. Therefore, an explanation is
that tissue damage and degradation lead to the release
o fF S T L 1i n t oS Fa n ds e r u m ,a n dt h er e s u l t i n ge l e v a t e d
F S T L 1l e v e l sc o n t r i b u t et or e l i e fo fO As y m p t o m sb y
inhibiting the production of MMPs and proinflamma-
tory cytokines. However, conflicting data indicate that
the increased FSTL1 expression aggravates the effects
of arthritis in a mouse model [8,15]. Further investiga-
tion is required to assess the exact roles of FSTL1 in
OA pathogenesis.
There are several limitations of this study. Firstly, the
SF and ST sample size from control trauma patients
was relatively small. Also, these samples were not
matched with OA samples by age and gender. However,
a lower number of control samples is generally inherent
to studies of human OA SF and tissue. Secondly, we
had limited clinical data for ST and SF because we
mostly used banked samples. Furthermore, relatively
fewer male OA patients had WOMAC and VAS scores.
These factors restricted our assessment to the relation-
ships between FSTL1 expression and the clinical charac-
teristics of these patients.
Conclusions
In summary, increased FSTL1 expression may be a char-
acteristic of OA patients. FSTL1 is a potential serum
biomarker that may reflect the severity of joint damage,
and further studies are required to evaluate its potential
application for monitoring the course of the disease and
the efficacy of therapies in OA patients.
Additional material
Additional file 1: Figure 1S. Distribution of serum FSTL1 concentrations
in 48 male and 120 female OA patients. Table 1S. Baseline characteristics
of 112 female patients with OA of the knee according to serum FSTL1
Table 5 Baseline characteristics of male OA patients according to serum FSTL1 levels.
Male serum FSTL1 levels (μg/L)
First quartile Second quartile Third quartile Fourth quartile P r
(1.19-3.81) (3.81-5.40) (5.88-8.62) (8.79-16.88)
Number 12 12 12 12
Age (years) 58 (47-61) 60 (54-74) 58 (52-72) 69 (65-79) 0.005 0.396
Disease duration (years) 0.1 (0.1-1.7) 0.6 (0.2-4.8) 1.5 (0.5-3.8) 2.5 (0.2-6.8) 0.004 0.405
Height, cm 170 (166-174) 168 (166-170) 166 (162-170) 169 (168-170) 0.378 -0.130
Weight, kg 72 (66-76) 68 (64-76) 67 (60-75) 69 (61-77) 0.376 -0.131
BMI 24.2 (22.8-26.2) 24.6 (22.7-26.3) 24.0 (21.6-25.8) 24.0 (21.4-26.4) 0.511 -0.097
Single/dual knee (hip) 11/1 12/0 9/3 9/3 0.130 0.222
Hypertension 4 (33%) 5 (42%) 5 (42%) 6 (50%) 0.486 0.103
Diabetes 2 (17%) 1 (8%) 1 (8%) 3 (25%) 0.687 0.060
Hs-CRP (mg/L) 1.4 (0.7-1.9) 1.1 (0.4-10.7) 1.4 (0.6-2.9) 2.4 (0.7-15.5) 0.056 0.278
ESR
a 8 (3-10) 4 (3-13) 5 (5-20) 12 (2-27) 0.957 -0.009
RF 3.8 (0.3-10.6) 7.2 (4.8-18.7) 11.1 (6.0-18.8) 9.0 (7.4-16.3) 0.021 0.332
Pain (VAS mm)
b 55 (40-60) 50 (20-70) 50 (35-80) 50 (40-80) 0.371 0.145
WOMAC score (all normalized/100)
c
Pain subscale 64 (57-68) 64 (64-71) 60 (51-68) 59 (52-61) 0.407 -0.152
Stiffness subscale 58 (46-75) 61 (45-81) 49 (45-79) 54 (43-58) 0.636 -0.087
Function subscale 65 (54-83) 77 (46-90) 69 (35-90) 60 (52-65) 0.617 -0.092
Total Score 63 (55-85) 69 (51-80) 63 (44-78) 59 (52-63) 0.342 -0.168
KL grade (0-4) 5/4/2/0/2 4/2/3/1/2 3/1/5/1/2 2/2/4/1/3 0.069 0.265
JSN 2 (17%) 3 (25%) 3 (25%) 4 (33%) 0.127 0.224
Data are number (%) or median (25
th to 75th percentile). Linear regression was used to evaluate the relationships between FSTL1 and baseline characteristics
and to calculate P values and the correlation coefficient, r. (Serum FSTL1 levels, disease duration, hs-CRP, ESR and RF in the male OA patients were not normally
distributed and were entered as ln-transformed variables).
aData from ESR were available for 39 patients;
bData for Pain VAS were available for 40 patients;
cData
from the total WOMAC score were available for 34 patients, and the pain subscale, stiffness subscale and function subscale were available for 32 patients,
respectively. BMI, body mass index; ESR, erythrocyte sedimentation rate; FSTL1, follistatin-like protein 1; Hs-CRP, high sensitivity C-reactive protein; JSN, joint
space narrowing; KL, Kellgren and Lawrence; OA, osteoarthritis; RF, rheumatoid factor; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster
Universities.
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Page 9 of 11levels. Table 2S. Baseline characteristics of 46 male patients with OA of
the knee according to serum FSTL1 levels.
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